gototopgototop

Main Menu

CSIR-IMTECH’s KNOW-HOW FOR RECOMBINANT STAPHYLOKINASE

Impact of the Technology:

This agent (a biogeneric) has previously shown, promise as an improved clot-buster in clinical trials abroad.

Summary of the work:

A recombinant strain has been developed for high level intracellular production of Staphylokinase in E. coli.
A high-efficiency facile two step protocol for purification of staphylokinase has also been developed.  
The complete technological package for the production for recombinant staphylokinase has been transferred to M/S Strides Arcolab Ltd., Bangalore.

Commercialization status:

The licensee is working on development of the commercial scale process with IMTECH’s advice at the pre-clinical testing stage.
 
This site is best viewed in Mozilla Firefox, Internet Explorer 8 and above at screen resolution of 1024 x 768 and above.